Molecular biology of Stat5a/b

The signal transducer and activator of transcription (Stat) protein family is composed of seven structurally and functionally related members: Stat1, Stat2, Stat3, Stat4, Stat5 (Stat5a and Stat5b), and Stat6. Stat5a and Stat5b are the two isoforms of Stat5 (794 amino acids for Stat5a and 786 amino acids for Stat5b), which share 93% homology at the amino acid level. Stat5a and Stat5b are encoded by separate genes which map to the human chromosome 17 (bands q11-1 to q22) [1-4]. Stat5a/b has six functional domains: N-terminal domain, coiled-coil domain, central DNA-binding domain, linker domain, SH2 domain, and transcriptional activation domain in the C-terminus [5]. The major difference between Stat5a and Stat5b resides in their C-termini, where there are 20 amino acids unique to Stat5a and 8 amino acids specific to Stat5b. Stat5a/b is both a cytoplasmic signaling molecule and a nuclear transcription factor. Stat5a/b is typically activated by receptor associated Janus kinases (Jaks) through phosphorylation of the specific tyrosine residue in the C-terminus (Y694 for Stat5a and Y699 for Stat5b) [3, 6]. Among the Jak protein family (Jak1, Jak2, Jak3 and Tyk2), Jak2 is the predominant kinase that activates Stat5a/b in response to prolactin (Prl) stimulation [7]. Phosphorylated Stat5a/b forms homo- or heterodimers, translocates into the nucleus, and binds to the Stat response element of the target genes to regulate specific gene transcription. Stat transcription factors are involved in the regulation of diverse biological responses, including differentiation, proliferation and apoptosis. Active Stat5a/b is frequently detected in several types of leukemia and hematopoietic disorders[8], and also in solid tumors, such as prostate cancer, breast cancer, uterine cancer, squamous cell carcinoma of the head and neck (SCCHN) [9, 10]. This review will focus on Stat5a/b in growth regulation of prostate cancer and as a target for pharmacological therapy development.

PrlR/Jak2/Stat5 signaling pathway in prostate cancer

The Prl/PrlR/Jak2/Stat5 signaling pathway provides critical survival advantage for prostate cancer cells. Human Prl is not only a pituitary-secreted hormone, but also a locally expressed...
cytokine in prostate cancer [11, 12]. The receptor for Prl (PrIR) is a member of the cytokine family, and Prl as well as PrIR are expressed in prostate epithelial cells [13]. Prl binding initiates a dimerization of two PrIRs and subsequent conformational change of the receptor. This conformational change induces receptor-associated Jak2 self-phosphorylation and subsequent phosphorylation of specific tyrosine residues in the PrIR. Stat5a/b can recognize the phosphorylated tyrosine residue and bind to the PrIR via the phosphotyrosine-SH2 domain interaction. Recruitment of Stat5a/b to the activated PrIR leads to a rapid phosphorylation of a conserved tyrosine residue in the C-terminus of Stat5a/b by activated Jak2. The phosphorylation of tyrosine residues Y694 and Y699 is critical for the activation of Stat5a and Stat5b, respectively. Phosphorylation of Stat5a/b results in their dissociation from the PrIR and subsequent formation of homo- or heterodimers through a reciprocal interaction between the phosphotyrosine peptide of one Stat5 and the SH2 domain of another Stat5 molecule [14, 15]. The Stat5 dimers translocate from the cytoplasm into the nucleus in an energy-dependent manner and may need the help of a chaperone protein MgcRacGAP [16, 17]. However, unphosphorylated Stat5a/b proteins may freely shuttle between nucleus and cytoplasm in the absence of cytokine activation, but the exact molecular mechanisms underlying the free traffic remain still largely unclear [16, 18]. In the nucleus, Stat5a/b dimers bind to the consensus DNA elements, usually called the GAS sites containing the motif TTCNNNGAA, and regulate transcription [19-21]. Moreover, the glycine residue at position 433 in Stat5b and a glutamic residue at a similar position in Stat5a may contribute to the distinct DNA binding specificities of Stat5a/b [22]. Additionally, the interactions of Stat5a vs. Stat5b with different co-regulators might be responsible for the non-redundant functions of Stat5a and Stat5b. The phosphorylation of serine residues in Stat5a/b may further modify the primary activating stimulus [23-25].

Stat5a/b as a therapeutic target for prostate cancer

Stat5a/b promotes prostate cancer progression to advanced disease

The expression of active nuclear Stat5a/b is associated with a loss of differentiation of prostate cancer. Stat5a/b is significantly more frequently active and nuclear in human prostate cancers of high histological grades as compared to intermediate or low grade prostate cancers [11, 27, 33]. Importantly, Stat5a/b activation in primary prostate cancer predicted early disease recurrence and shorter progression-free survival after radical prostatectomy [33]. Even in intermediate Gleason grade prostate cancers, active Stat5a/b remained an independent prognostic marker of early disease recurrence and was associated with progressive disease [33]. Moreover, Stat5a/b was active in 95% of castration-resistant clinical human prostate cancers [34]. Mechanistically, active Stat5a/b signaling pathway increased transcriptional activity of androgen receptor. Androgen receptor, in turn, increased transcription activity of Stat5a/b. Stat5a/b potentially contributes to castration-resistant growth of prostate cancer [34]. Intriguingly, Prl/PrIR/Jak2/Stat5 signaling pathway may promote the initiation of prostate tumorigenesis by nourishing basal-/stem-like cell sub-populations [12]. The basal-/stem-like cells may be the source of castration-resistant recurrent prostate cancer [12].

Besides of being a key growth and survival promoting factor, active Stat5 was shown to induce metastatic progression of human prostate cancer cells in in vivo experimental metastases assay [31]. In addition, Stat5a/b promoted cell
migration and invasion, heterotypic adhesion of prostate cancer cells to endothelial cells and suppressed homotypic adhesion of prostate cancer cells [31]. Therefore, Stat5a/b may serve as a potential therapeutic protein in disseminated prostate cancer.

**Targeting Stat5 signaling pathway in prostate cancer**

The PrlR/Jak2/Stat5 signaling pathway can be pharmacologically targeted at different levels (Figure 1). First, the upstream activators of Stat5a/b can be pharmacologically inhibited. Local production of Prl is increased in high histological grade of prostate cancers [27], and autocrine production of Prl may be responsible for the activation of Stat5a/b and growth advantage of prostate cancer cells as well as basal-/stem-like cell subpopulations [12, 29]. Targeting the activation of PrlR is of great interest in this aspect. Two promising PrlR antagonists have been developed: the S179D-hPrl [35] and the more specific human PrlR antagonist Δ1-
9G129R-hPrl \([12, 29, 36]\). Dr. Rouet and colleagues recently found that \(\Delta 1–9\)-G129R-hPRL prevented early stages of prostate tumorigenesis by reducing or inhibiting Stat5a/b activation, cell proliferation, abnormal basal-cell pattern, and frequency or grade of intraepithelial neoplasia \([12]\).

Second, the direct activator of Stat5a/b, Jak2 kinase can be targeted by specific small-molecule inhibitors. Jak2 inhibitors are currently in active development for myeloproliferative disorders, leukemias and solid tumors \([37-39]\). Since Jak2 is the major kinase responsible for the activation of Stat5a/b in prostate cancer, Jak2 inhibitors may provide therapeutic agents for further clinical development for prostate cancer therapy. AZD1480 from AstraZeneca (chemical structure shown in Figure 2) is one such small molecule Jak2 inhibitor with promising pre-clinical activity \([40]\).

Third, targeting Stat5a/b protein itself is another attractive strategy, and direct inhibition of Stat5a/b is less likely to result in unintentional inhibition of additional parallel signaling pathways. The loss-of function strategy could be applied to knockdown of the expression of Stat5a/b, such as antisense oligodeoxynucleotide or siRNA against Stat5a/b, and Stat5a and Stat5b could be targeted individually or simultaneously. In addition, small-molecular compounds targeting the SH2 domain of Stat5a/b can be developed. Theoretically, successful binding of the small-molecule compounds to the critical amino acids of the SH2-domain can lead to inhibition of both Stat5a/b dimerization and its recruitment to an activated receptor (such as PrlR) for its phosphorylation/activation. By using fluorescence polarization assay, Dr. Muller and colleagues \([41]\) discovered a series of compounds including the most potent \(N'-(4-Oxo-4H-chromen-3-yl)methylene)nicotinohydrazide\) with an IC\(_{50}\) of 47 \(\mu\)M (chemical structure shown in Figure 3) as Stat5b inhibitors, with lesser inhibition to the function of the SH2 domains of Stat3, Stat1, and of the tyrosine kinase Lck. The chromone-derived acyl hydrazone inhibitor is aimed to block the binding of Stat5a/b to activated erythropoietin (EPO) receptor. However, there is no data about whether the Stat5b inhibitor, chromone-derived acyl hydrazone, also inhibits Stat5a or Stat5b through its SH2 domain binding to activated PrlR and thereafter the activation and dimerization of Stat5a/b. It is worthwhile to investigate the Stat5 inhibitor, \(N'-(4-Oxo-4H-chromen-3-yl)methylene)nicotinohydrazide\), for its activity on interfering with the function of Stat5a/b in prostate cancer cells. Peptide aptamer could be an additional strategy to directly target Stat5a/b for drug discovery and development \([42]\). Peptide aptamers which specifically interact with the Stat3 dimerization domain have been explored and they inhibited Stat3 DNA binding and suppressed Stat3 trans-activation in EGF-responsive cells \([43]\). Peptide aptamers against Stat5a/b have not been reported.

**Summary**

Targeting the PrlR/Jak2/Stat5 signaling pathway provides a promising strategy for therapy development for prostate cancer. PrlR, Jak2 and

---

**Figure 2.** Chemical structure of the Jak2 inhibitor AZD1480.

**Figure 3.** Structure of the SH2 domain inhibitor of Stat5b, \(N'-(4-Oxo-4H-chromen-3-yl)methylene)nicotinohydrazide\).
Stat5a/b inhibitors are underway in pre-clinical development and are expected to enter phase I/II clinical trials within the next 2-3 years. Importantly, in addition to being a prognostic marker, active Stat5a/b may potentially serve as a predictive marker of responsiveness to therapies targeting the PrlR/Jak2/Stat5a/b signaling pathway and, therefore, provide a mechanism for personalized medicine for prostate cancer patients.

Please address correspondence to: Marja T. Nevalainen, MD, PhD, Department of Cancer Biology, Urology, Medical Oncology, Kimmel Cancer Center, Thomas Jefferson University, 233 S. 10th Street, BLB 309, Philadelphia, PA 19107. Tel: 215-503-9250, Fax: 215-503-9245, E-mail: marja.nevalainen@jefferson

References

[22] Boucheron C, Dumon S, Santos SC, Moriggl R, Hennighausen L, Gisselbrecht S and Gouilleux F. A single amino acid in the DNA binding regions...


